Studies whether fluorescein eye dye affects kidneys in people with diabetes and kidney disease
Tests fluorescein eye imaging dye in adults with diabetes and advanced chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease
Key facts
- Where
- Beirut, LebanonSee the site
Where in Lebanon
- Faculty of Medicine, Saint Joseph University of BeirutBeirut, LebanonNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Saint-Joseph University
- Trial code
- NCT06760650
- Record updated
- 7 January 2025
- Original description
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.Read full original descriptionShow less
Fluorescein-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.
Inclusion: >18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b to 5 (eGFR<45 mL/min/1.73 m2).
Exclusion: Patients who had a treatment modification one week before the intervention; Patients who are allergic to fluorescein; Patients who do not give their consent; Patients who are on dialysis; Patients who had fever, vomiting, diarrhea or any dehydration 48 hours before the intervention.